Epidiolex, Sativex maker GW Pharmaceuticals reports Q1 revenue, loss improvement

United Kingdom-based GW Pharmaceuticals showed revenue of $39.2 million for the quarter ended March 31, 2019, compared with $3 million in the same period a year ago.

The maker of cannabis-derived medications, including Sativex and Epidiolex, recorded a net loss for the quarter of $50.1 million compared with a year-ago net loss of $69.5 million.

GW Pharma trades on the Nasdaq under the ticker symbol GWPH.